Table 1.
Patient and tumor characteristics of the study cohort.
| Clinicopathologic Characteristics | Number (%) |
|---|---|
| Age (years) | |
| Median (range) | 50 (30–74) |
| T stage | |
| T1 | 47 (40.5) |
| T2 | 55 (50.5) |
| T3 | 7 (6.4) |
| N stage | |
| N0 | 74 (67.9) |
| N1 | 16 (14.7) |
| N2 | 6 (5.5) |
| N3 | 13 (11.9) |
| Histologic grade | |
| 1 | 4 (3.7) |
| 2 | 21 (19.3) |
| 3 | 84 (77.1) |
| EIC | |
| Absent | 96 (88.1) |
| Present | 13 (11.9) |
| Lymphovascular invasion | |
| Absent | 83 (76.1) |
| Present | 26 (23.9) |
| Ki-67 labeling index | |
| <20% | 28 (25.7) |
| ≥20% | 81 (74.3) |
| Stromal TIL percentage | |
| 0–10% | 18 (16.5) |
| 11–40% | 44 (40.4) |
| ≥40% | 47 (43.1) |
| PD-L1 expression in tumor cells | |
| <1% | 54 (49.5) |
| ≥1% | 55 (50.5) |
| PD-L1 expression in lymphocytes | |
| <1% | 67 (61.5) |
| ≥1% | 42 (38.5) |
| P53 overexpression | |
| Absent | 46 (42.2) |
| Present | 63 (57.8) |
| Adjuvant therapy | |
| Chemotherapy | 107 (99.1) |
| Radiation | 82 (75.2) |